◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Inventurus Knowledge Solutions Limited (IKS)

Name: Inventurus Knowledge Solutions Limited（IKS）— 财务报表历史
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

来自官方财务报表的收入、利润与现金流历史。

Healthcare · 华尔街（美国） · 最近更新： 2026-09-20

Inventurus Knowledge Solutions Limited operates as a technology-enabled healthcare solutions provider. The company offers a care enablement platform and associated services predominantly to healthcare enterprises in the United States, Canada, and Australia. The company offers a platform that serves healthcare organizations, including health systems/ integrated delivery networks, academic medical centers, multi-specialty medical groups, single-specialty medical groups, ancillary healthcare organizations, and other outpatient healthcare delivery organizations.

关键数据

市值: ₹299 billion
收入（截至 2026-03-31 财年）: ₹31.9B
净利润: ₹7.2B
毛利率: 49.5%
净利率: 22.6%

查看交互式图表与完整报表 →

年度利润表

利润表	2026-03-31	2025-03-31	2024-03-31	2023-03-31
总收入	₹31.9B	₹26.6B	₹18.2B	₹10.3B
毛利	₹15.8B	₹11.5B	₹8.4B	₹5.2B
营业利润（EBIT）	₹9.1B	₹6.5B	₹4.7B	₹3.7B
净利	₹7.2B	₹4.9B	₹3.7B	₹3.1B

来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。

资产负债表、现金流、季度数据与完整财务比率见 IKS 交互式查看器。 /companies/us/IKS

类似公司

本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。

English version →全部股票

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.